Lukewarm response to cold war on international pricing index

Why PhRMA and BIO find it hard to kill the international pricing index

PhRMA and BIO have gone to war against the Trump administration’s proposal to reference some Medicare Part B drug prices to a basket of prices paid in other countries, but they haven’t found many allies in Congress.

Lobbying campaigns and advertising by the trade associations, the U.S. Chamber of Commerce and several conservative groups have not led a single Republican Senator to publicly condemn the international pricing index (IPI) proposal.

Sens. Lamar Alexander (R-Tenn.), chair of the Health, Education, Labor and Pensions (HELP) Committee, and

Read the full 846 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE